Achieving Sub-3-Week PCV Manufacturing: Leveraging Biopsy Timing & Dendritic Cell Delivery to Eliminate Bottlenecks & Improve Access
11:30 am - Tuesday 18th November 2025
• Coordinating tumor biopsy with standard-of-care procedures to streamline sample collection and preserve cell viability
• Using biologically driven antigen selection and dendritic cell delivery to bypass lengthy genomic prediction and adjuvant formulation
• Reducing turnaround time to under 3 weeks and costs below $10K to improve patient access